Ongoing rubella epidemic in Osaka, Japan, in 2018–2019

Authors

  • Daiki Kanbayashi Osaka Institute of Public Health, Osaka, Japan
  • Takako Kurata Osaka Institute of Public Health, Osaka, Japan
  • Hideyuki Kubo Osaka Institute of Public Health, Osaka, Japan
  • Atsushi Kaida Osaka Institute of Public Health, Osaka, Japan
  • Seiji P Yamamoto Osaka Institute of Public Health, Osaka, Japan
  • Kazutaka Egawa Osaka Institute of Public Health, Osaka, Japan
  • Yuki Hirai Osaka Institute of Public Health, Osaka, Japan
  • Kazuma Okada Osaka Institute of Public Health, Osaka, Japan
  • Ryo Ikemori Osaka Institute of Public Health, Osaka, Japan
  • Takahiro Yumisashi Osaka Institute of Public Health, Osaka, Japan
  • Akira Yamamoto Sakai City Institute of Public Health, Osaka, Japan
  • Hideki Yoshida Osaka City Health Center, Osaka, Japan
  • Takanori Hirayama Osaka Prefectural Government, Osaka, Japan
  • Kazuyoshi Ikuta Osaka Institute of Public Health, Osaka, Japan
  • Kazushi Motomura Osaka Institute of Public Health, Osaka, Japan

DOI:

https://doi.org/10.5365/wpsar.2019.10.3.001

Abstract

A large rubella epidemic is currently ongoing since 2018 in Osaka, Japan. The detected rubella viruses were classified into genotypes 1E lineage 2 and 2B lineage 1. These strains may have been imported from endemic countries, and these viruses spread within the susceptible population.

 

References

Reef S, Plotkin SA. Rubella vaccine. In: Plotkin SA, Orenstein W, Offit P, editors. Vaccines, 6th ed. Philadelphia: Saunders; 2013. p. 688–717.

Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clinical Infectious Diseses. 2006;43(Suppl 3):S164–8.

The Decade of Vaccine Collaboration. Global Vaccine Action Plan 2011-2020. [Webpage on the Internet]. 2012 [cited; Available from: http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/]

National Institute of Infectious Diseases, and Tuberculosis, and Infectious Diseases Control Division, Ministry of Health, Labor, and Welfare, Japan. Rubella and congenital rubella syndrome in Japan as of January 2018. Infectious Agents Surveillance Report. 2018;39:p. 29-31.

Kanbayashi D, Kurata T, Nishino Y, Orii F, Takii Y, Kinoshita M, et al. Rubella Virus Genotype 1E in Travelers Returning to Japan from Indonesia, 2017. Emerging infectious diseases. 2018 Sep;24(9):1763-5.

National Institute of Infectious Diseases (Japan). Cumulative rubella cases by week, 2012-2018 (week 1-52) (based on diagnosed week as of January 7, 2019). 2018 [cited 2019 4 June]; Available from: http://www.niid.go.jp/niid//images/idsc/disease/rubella/2018pdf/rube18-52.pdf

National Institute of Infectious Diseases (Japan). Cumulative rubella cases by week, 2013-2019 (week 1-27). 2019 [cited 2019 22 July]; Available from: https://www.niid.go.jp/niid//images/idsc/disease/rubella/2019pdf/rube19-27.pdf

National Institute of Infectious Diseases (Japan). National Epidemiological Surveillance of Vaccine-Preventable Diseses; Seroprevalence of VPDs. 2011, 2017 [cited; Available from: https://www.niid.go.jp/niid/ja/y-graphs/1600-yosoku-index-e.html

National Institute of Infectious Diseases (Japan). Trends in Notifications of Imported Cases among Select Notifiable Infectious Diseases in Japan. 2019 [cited 2019 9 May]; Available from: https://www.niid.go.jp/niid/images/epi/imported/PDF/20190318_Webup%20Imported%20IDs%20revised.pdf

Mori Y, Miyoshi M, Kikuchi M, Sekine M, Umezawa M, Saikusa M, et al. Molecular Epidemiology of Rubella Virus Strains Detected Around the Time of the 2012-2013 Epidemic in Japan. Frontiers in microbiology. 2017;8:1513.

Downloads

Published

30-06-2020

How to Cite

1.
Kanbayashi D, Kurata T, Kubo H, Kaida A, Yamamoto SP, Egawa K, Hirai Y, Okada K, Ikemori R, Yumisashi T, Yamamoto A, Yoshida H, Hirayama T, Ikuta K, Motomura K. Ongoing rubella epidemic in Osaka, Japan, in 2018–2019. Western Pac Surveill Response J [Internet]. 2020 Jun. 30 [cited 2026 Apr. 1];11(2). Available from: https://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/697

Issue

Vol. 11 No. 2 (2020): April – June

Section

Brief Report

License

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

When the Licensor is an intergovernmental organization, disputes will be resolved by mediation and arbitration unless otherwise agreed.

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.